Search | Clinical Trials Finder

Conditions: Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid Use Disorder, Back Pain, Stress
Interventions: Placebo, Oxycodone, Naloxone; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heroin Dependence, Opioid-Related Disorders
Interventions: Hydromorphone; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Noncancer Pain
Interventions: oxycodone HCl and naltrexone HCl extended-release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 32
States / cities: DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more

Conditions: Acute Pain
Interventions: Oxymorphone immediate release; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more

Conditions: Rotator Cuff Tear
Interventions: Rotator cuff repair, Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole, Hydrocodone/Acetaminophen; Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Oxycodone, Placebo oral tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 40 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Tucker, Georgia

Conditions: Chronic Pain
Interventions: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain, Acute
Interventions: Ketamine, Morphine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgery, Pain, Post Operative
Interventions: NSAID, Opioid, Acetaminophen, Ibuprofen; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 12 Years to 20 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 1 more

Conditions: Pain
Interventions: Hydromorphone, Morphine; Drug
Lead sponsor: Grace Shih, MD; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Osteoarthritis, Knee, Arthroplasty, Replacement, Knee
Interventions: Liposomal bupivacaine, 266mg, Bupivacaine 0.5 % with Epinephrine, Ketorolac 30mg, Morphine 10mg, Bupivacaine 0.25% with Epinephrine; Drug
Lead sponsor: Holy Cross Hospital, Florida; Other
Eligibility: 18 Years to 88 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Multiple Sclerosis, Relapsing
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Pain, Morphine Adverse Reaction
Interventions: Epidural Morphine, Epidural Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Substance Use Disorder (SUD)
Interventions: Regional Anesthesia, Hydromorphone Patient Controlled Analgelsic, Epidural local anesthetic infusion; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Pain
Interventions: Hydromorphone Hydrochloride, Programmable Implantable pump; Drug · Device
Lead sponsor: Piramal Critical Care, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Locally Advanced Head and Neck Cancer
Interventions: Xtampza ER; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Traumatic Brain Injury
Interventions: Mnemonic strategy training (MST), Repeated exposure (XP), Subtracting Cues training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 88 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Multiple Sclerosis
Interventions: Blood draw for future biomarker analysis; Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Pain, Perioperative/Postoperative Complications, Sarcoma
Interventions: fentanyl citrate, hydromorphone hydrochloride, ropivacaine hydrochloride; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Intra-abdominal Cancer
Interventions: Hydrocodone, Tramadol, Oxycodone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sedation
Interventions: Midazolam, Fentanyl/Morphine, Dexmedetomidine; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 28 Weeks to 44 Weeks
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 17
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 14 more

Conditions: Degenerative Joint Disease
Interventions: L2 paravertebral block, periarticular injection group; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

The Effect of NSAIDs After a Rotator Cuff Repair Surgery.

Are Opioids Needed After ACL Reconstruction

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Comparison of Low-dose Ketamine to Opioids in the Management of Acute Pain in Patients Presenting to the Emergency Department With Long Bone Fractures

Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial

Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries

A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Two Dose Epidural Morphine for Post-cesarean Analgesia

Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.

Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration

Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer

Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Post-operative Pain After Direct Anterior Total Hip Arthroplasty